Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Open-label, Prospective Single-arm, Multi-center Clinical Trial to Evaluate if Adding Venetoclax to Patients on Covalent BTKi For 1L CLL Can Achieve Deep Durable Remissions (by UMRD 10^-4) to Allow Off-treatment Period

NCT06524375 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT06524375
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06524375 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Open-label, Prospective Single-arm, Multi-center Clinical Trial to Evaluate if Adding Venetoclax to Patients on Covalent BTKi For 1L CLL Can Achieve Deep Durable Remissions (by UMRD 10^-4) to Allow Off-treatment Period
Lead sponsor
Genentech, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 9, 2024
Completion date
January 31, 2030
Enrollment
118 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia